1. Novo Ventures sows $25M into accelerator for projects with the Broad Institute — Amgen trimming jobs from operations, R&D, and sales — Novartis looking to buy Medicines Co — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Pacira Contract

Discussion in 'Innovex' started by Anonymous, Dec 5, 2011 at 11:12 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    This place will not be around 2 more years
     
  2. Anonymous

    Anonymous Guest

    so is my favorite former DM still around, andy ddddddck, lizard eyes, vest and all????? bet he's doing oh so well, he was so ggoooodd
     
  3. Anonymous

    Anonymous Guest

    David M. Stack
    Salary $462,000
    Bonus $231,000
    Total Annual Compensation $693,000
    Stock Options*
    All Other Compensation $2,879
    Exercisable Options 409,021
    Unexercisable Options 541,100
    Total Number of Options 950,121
    Total Compensation*
    Total Annual Cash Compensation $695,879
    Total Short Term Compensation $693,000
    Other Long Term Compensation $2,879
    Total Calculated Compensation $3,173,91
     
  4. Anonymous

    Anonymous Guest

    Show me some money!
     
  5. Anonymous

    Anonymous Guest

    With all the boxes sold in TX, Mayo, UPMC, and Cleveland clinic I would hope that the comp plan would be more generous in the coming year. Ya right.
     
  6. Anonymous

    Anonymous Guest

    those places are carrying the whole country/company. when will wall street realize its a straw house?
     
  7. Anonymous

    Anonymous Guest

    That's BS, Look at Des Moines and Omaha. The Company is doing well. Pull your head out of your ass
     
  8. Anonymous

    Anonymous Guest

    What's this I'm hearing about the clinical reps getting huge stock options while sales is given basically nothing?
     
  9. Anonymous

    Anonymous Guest

    Those areas are only doing well because of the Ortho distributor reps. Those guys are the ones driving the business and getting the product in the hospitals. The clinical specialist don't know how to talk to surgeons and the Pacira sales reps are idiots. Now that Ortho is blowing up they are pushing out the distributor reps. Seems like a brilliant strategy.
     
  10. Anonymous

    Anonymous Guest

    So the sales people are idiots you say. Most of us have had a long highly successful career in the medical field.

    If is any failure it is your lack of understanding of this market and your own analytical skills

    Go back underneath your rock!
     
  11. Anonymous

    Anonymous Guest

    Spank micky
     
  12. Anonymous

    Anonymous Guest

    A large majority of the reps are not the best and brightest. A lot have really just ridden the sales pushed by surgeon word of mouth and not actually driven the numbers through their own actions. If Pacira fire all the reps tomorrow I would be willing to be the sales numbers would stay close to the same or may continue to grow.
     
  13. Anonymous

    Anonymous Guest

    You are an idiot with no clue on what it takes to work it through the system. Your comments show your ignorance and lack of understanding of how the product works and what it takes to make it available for a surgeon. Enjoy your idiocy!
     
  14. Anonymous

    Anonymous Guest

    What a dumb ass, reps drive this drug. With them number would be on a downward trend.


    That's a fact,,,,.tard
     
  15. Anonymous

    Anonymous Guest

    Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter

    PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Warning Letter (attached for reference) from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) referencing certain promotional materials on EXPAREL® (bupivacaine liposome injectable suspension).
     
  16. Anonymous

    Anonymous Guest

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pacira Pharmaceuticals, Inc. - PCRX

    NEW YORK, Sept. 25, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company") (PCRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.

    The investigation concerns whether Pacira and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

    On September 25, 2014, the Company announced that it received a Warning Letter from the U.S. Food and Drug Administration's ("FDA") Office of Prescription Drug Promotion referencing certain promotional materials for EXPAREL® (bupivacaine liposome injectable suspension), an injectable drug that numbs post-surgical pain.

    In the letter, the FDA said Pacira promotes its drug EXPAREL as being able to work for up to 72 hours when it has only been approved for 24-hour pain relief. "These claims overstate Exparel's efficacy and are misleading," the FDA said in the letter.

    On this news, shares of Pacira fell $4.70 per share to $101.58, or more than 4.42%, in intraday trading on September 25, 2014.

    The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

    CONTACT:
    Robert S. Willoughby
    Pomerantz LLP
    rswilloughby@pomlaw.com
     
  17. #317 Anonymous, Apr 16, 2015 at 6:03 PM
    Last edited by a moderator: Aug 9, 2016 at 5:03 PM
    Anonymous

    Anonymous Guest

    Ha Ha Ha ha ha ha ha ha ha

    Pacira Receives Subpoena from the U.S. Department of Justice

    * Reuters is not responsible for the content in this press release.

    Pacira Receives Subpoena from the U.S. Department of Justice

    Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it received a subpoena from the U.S. Department of Justice, U.S. Attorney’s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to the product EXPAREL® (bupivacaine liposome injectable suspension). Pacira intends to cooperate with the government’s investigation.